Butturini A, Rivera G K, Bortin M M, Gale R P
Lancet. 1987 Feb 21;1(8530):429-32. doi: 10.1016/s0140-6736(87)90128-0.
The best therapy for children with acute lymphoblastic leukaemia (ALL) who have an initial bone marrow relapse and subsequently achieve second remission is controversial. Some findings suggest that bone marrow transplantation (BMT) is better than chemotherapy whereas others do not. An analysis of 871 children treated by BMT or chemotherapy showed that outcome was correlated with risk factors at diagnosis and with length of first remission. BMT seemed superior in patients who relapsed within 18 months of first remission while on maintenance chemotherapy. BMT was not demonstrably superior in patients who relapsed more than 18 months after first remission. The choice of treatment in childhood ALL must be based on prognostic variables at diagnosis and on the circumstances of the relapse.
对于初发骨髓复发后又获得第二次缓解的急性淋巴细胞白血病(ALL)患儿,最佳治疗方法存在争议。一些研究结果表明,骨髓移植(BMT)优于化疗,而另一些研究则不然。一项对871例接受BMT或化疗的患儿的分析表明,治疗结果与诊断时的危险因素以及首次缓解期的长短相关。在维持化疗期间首次缓解后18个月内复发的患者中,BMT似乎更具优势。首次缓解后18个月以上复发的患者中,BMT并没有明显的优势。儿童ALL的治疗选择必须基于诊断时的预后变量以及复发情况。